✦ LIBER ✦

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

✍ Scribed by Cosette M Wheeler; Xavier Castellsagué; Suzanne M Garland; Anne Szarewski; Jorma Paavonen; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Dan Apter; Henry Kitchener; Júlio C Teixeira; S Rachel Skinner; Unnop Jaisamrarn; Genara Limson; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Diane M Harper; Warner Huh; Karin Hardt; Toufik Zahaf; Dominique Descamps; Frank Struyf; Gary Dubin; Matti Lehtinen

Book ID: 117785815
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 221 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70287-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of human papillomavirus (HPV)-1

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

✍ J Paavonen; P Naud; J Salmerón; CM Wheeler; S-N Chow; D Apter; H Kitchener; X Ca 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 303 KB

Overall efficacy of HPV-16/18 AS04-adjuv

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

✍ Matti Lehtinen; Jorma Paavonen; Cosette M Wheeler; Unnop Jaisamrarn; Suzanne M G 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 486 KB